The Nicotinamide N Methyltransferase pipeline drugs market research report outlays comprehensive information on the Nicotinamide N Methyltransferase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Nicotinamide N Methyltransferase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Musculoskeletal Disorders, Oncology, and Gastrointestinal which include the indications Obesity, Type 2 Diabetes, Musculoskeletal Disorders, Sarcopenia, Solid Tumor, Glioblastoma Multiforme (GBM), and Metabolic Dysfunction-Associated Steatohepatitis (MASH). It also reviews key players involved in Nicotinamide N Methyltransferase targeted therapeutics development with respective active and dormant or discontinued products.
The Nicotinamide N Methyltransferase pipeline targets constitutes close to 11 molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 6, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Nicotinamide N Methyltransferase overview
Nicotinamide N methyltransferase (NNMT) plays a crucial role in regulating cellular methylation potential, by consuming S-adenosyl-L-methionine and limiting its availability for other methyltransferases. NNMT actively mediates genome-wide epigenetic and transcriptional changes through hypomethylation of repressive chromatin marks, such as H3K27me3. It catalyzes the N-methylation of nicotinamide using the universal methyl donor S-adenosyl-L-methionine to form N1-methylnicotinamide and S-adenosyl-L-homocysteine, a predominant nicotinamide/vitamin B3 clearance pathway.
For a complete picture of Nicotinamide N Methyltransferase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
